Xanthine Oxidase is an enzyme, which oxidizes hypoxanthine to xanthine, and xanthine to uric acid. It is widely distributed throughout various organs including the liver, gut, lung, kidney, heart, brain and plasma. It is involved in gout pathogenesis. In this study, we have performed Comparative Molecular Field Analysis (CoMFA) on a series of 2-(indol-5-yl) thiazole derivatives as xanthine oxidase (XO) inhibitors to identify the structural variations with their inhibitory activities. Ligand based CoMFA models were generated based on atom-by-atom matching alignment. In atom-by-atom matching, the bioactive conformation of highly active molecule 11 was generated using systematic search. Compounds were aligned using the bioactive conformation and it is used for model generation. Different CoMFA models were generated using different alignments and the best model yielded a cross-validated q 2 of 0.698 with five components and non-cross-validated correlation coefficient (r 2 ) of 0.992 with Fisher value as 236.431, and an estimated standard error of 0.068. The predictive ability of the best CoMFA models was found to be r 2 p r e d 0.653. The CoMFA study revealed that the R 3 position of the structure is important in influencing the biological activity of the inhibitors. Electro positive groups and bulkier substituents in this position enhance the biological activity.
Introduction
Xanthine oxidase is an enzyme that generates reactive oxygen species. The enzyme oxidizes hypoxanthine to xanthine, and xanthine to uric acid, producing hydrogen peroxide. XO is widely distributed throughout various organs. This includes the liver, gut, lung, kidney, heart, brain and plasma [1] with the highest levels being found in the gut and the liver [2] . It is localized to the capillary endothelial cells, in the myocardium [3] . XO is the only enzyme capable of catalyzing the formation of urate in man [4] . There is a large variability in human XOR expression which can be up to three-fold and on average 20% higher in men than in women [5] .
The active form of the enzyme is a homodimer of molecular mass 290 kDa, with each of the monomers acting independently in catalysis. Each subunit mole-cule is composed of an N-terminal 20-kDa domain containing two iron sulfur centers, a central 40-kDa FAD domain, and a C-terminal 85-kDa molybdopterin-binding domain with the four redox centers aligned in an almost linear fashion. The hydroxylation of xanthine takes place at the molybdopterin center, and the electrons thus introduced are rapidly transferred to the other linearly aligned redox centers [6, 7] .
Xanthine oxydase is involved in gout pathogenesis. Gout is a disease in which defective metabolism of uric acid causes arthritis, especially in the smaller bones of the feet, deposition of chalk-stones, and episodes of acute pain. Gout is a common disease with prevalence of >2% in men older than 30 years and in woman older than 50 years according to the Third National Health and Nutrition Examination Survey (1988) (1989) (1990) (1991) (1992) (1993) (1994) [8, 9] . Gout occurs in individuals who have high serum uric acid levels, in response to precipitation of monosodium urate monohydate crystals in various tissues, followed by an inflammatory response. Typical symptoms of gout include acute recurrent gouty arthritis, a tophinodular collection of monosodium urate crystals and uric acid urolithiasis [10] . XO also plays an important role in 3D-QSAR Studies on 2-(indol-5-yl)thiazole Derivatives as Xanthine Oxidase (XO) Inhibitors 259 various forms of ischemic and other types of tissue and vascular injuries, inflammatory diseases, and chronic heart failure [11] . A xanthine oxidase inhibitor is any substance that inhibits the activity of xanthine oxidase. Xanthine oxidase inhibitors are of two kinds: purine analogues and others. Purine analogues include allopurinol, oxypurinol, and tisopurine. Others include febuxostat, topiroxostat, and inositols (phytic acid and myo-inositol). These commercially available drugs have certain disadvantages. For Example, Allopurinol has two important disadvantages. First, its dosing is complex [12] . Second, some patients are hypersensitive to the drug, [13] therefore its use requires careful monitoring. Allopurinol has rare but potentially fatal adverse effects involving the skin. The most serious adverse effect is a hypersensitivity syndrome consisting of fever, skin rash, eosino-philia, hepatitis, worsened renal function, and, in some cases, allopurinol hypersensitivity syndrome [13] . The adverse effects of febuxostat include nausea, diarrhea, arthralgia, headache, increased hepatic serum enzyme levels and rash [14] . Hence, the discovery of structurally diverse XO inhibitors becomes imoportant.
Materials and Methods

Data Set
A series of 21 compounds with their biological activities were taken from the literature [15] . The compounds were divided into training set and test set molecules. The test set molecules were selected manually in order to cover low, middle, and high biological activity from the dataset. For QSAR analysis, the given inhibitory concentration values (IC 50 ) were pIC 50 = −log (IC 50 ).
The structures and biological activities of all compounds including both training set and test set molecules is shown in Table 1 .
Partial Atomic Charge Calculation and Bioactive Conformation Determination
For each compound, the partial atomic charges were assigned by utilizing Gasteiger Hückel method available in SYBYLX 2.1 package (Tripos Inc., St. Louis, MO, USA). The bioactive conformation of the highly active compound 11 was determined using systematic search method. The obtained conformation from these methods was used as the template to perform alignment for CoMFA calculations. During systematic search all rotatable bonds were searched with incremental dihedral angle from 120 o and the lowest energy conformer was assumed as bioactive conformer and was chosen for subsequent QSAR modeling. Bioactive conformations for other compounds were determined by systematic conformer search for the additional moieties, by keeping core part constrained. It was seen that, the common scaffold of every inhibitor occupies the same area in 3D space. The matching atoms were selected by maximum common substructure (MCS) as shown in Fig. 1(a) and the alignment of all the molecules are represented in Fig. 1(b) .
CoMFA Model Calculation
CoMFA was performed with the generally used steric and electrostatic fields in SYBYL-X 2.0. The aim of CoMFA analysis is to derive a correlation between the biological activity of a set of molecules and their 3D shape, electrostatic and hydrogen bonding characteristics. This correlation is derived from a series of superimposed conformations aligned using the atom-by-atom matching. Each conformation is taken in turn, and the molecular fields around it are calculated. The electrostatic and steric (van der Waals interactions) fields are measured at the lattice points of a regular Cartesian 3D grid. The lattice spacing is typically 2 Å. The lattice was defined automatically and is extended 4 units past Van der Waals volume of all molecules in x, y, and z directions. Using Tripos force field, the Van der Waals potential and columbic terms, which represent steric and electrostatic fields, respectively, were calculated. A distance-dependent dielectric constant was used. The CoMFA method was performed using steric and electrostatic fields with standard ±30 kcal/mol cutoffs. A series of models were constructed with an increasing number of partial least squares (PLS) analysis factors. The numbers of components in the PLS models were optimized by using the cross-validated correlation coefficient (q 2 ), non-cross-validated correlation coefficient (r 2 ), standard error estimate (SEE) and Fisher's values (F), etc., which were obtained from the leave-one-out (LOO) cross-validation procedures [16, 17] . After the optimal number of components was determined, a noncross-validated analysis was carried out without column filtering.
Partial Least Squares (PLS) Analysis
The CoMFA equation was established by partial least-squares (PLS) analysis between biological activity and molecular parameters. By using the PLS method [18, 19] the CoMFA descriptors were linearly correlated with the biological activity values. The CoMFA cutoff values were set to 30 kcal⁄mol for both the steric and electrostatic fields. Leave-one-out method (LOO Method) was used to perform the cross-validation analysis. The cross-validated correlation coefficient (q 2 ) was calculated using the following equation:
where γ pred , γ actual , and γ mean are the predicted, actual, and mean values of the target property (pIC 50 ), respectively. ) The predictive power of CoMFA models were determined from the set of eight test molecules which was excluded during model development. [20] [21] [22] [23] [24] In the structural preparation of test set molecules, sketching and optimization was same as the training set molecules. The activity of the test set was predicted by using model derived from training set. The predictive correlation coefficient (r 2 pred ), based on the test set molecules, is defined as:
Predictive Correlation Coefficient (r
where, PRESS is the sum of the squared deviation between the predicted and actual activity of the test set molecules, and SD is defined as the sum of the square deviation between the biological activity of the test set compounds and the mean activity of the training set molecules.
CoMFA Contour Maps
CoMFA analysis generates color-coded contour maps that represent regions in three dimensional space where changes in the steric and electrostatic fields of a compound correlate strongly with changes in its biological activity. Contour maps were generated as a scalar product of coefficients and standard deviation (StDev * Coeff) associated with each column. Favored levels were fixed at 70% and disfavoured levels were fixed at 30%. The contours for steric fields are shown in green (more bulk favored) and yellow (less bulk favored). The electrostatic field contours are displayed in red (electronegative substituents favored) and blue (electropositive substituents favored) colors.
Results and Discussion
In the present work, ligand-based CoMFA models was generated on a series of 2-(indol-5-yl) thiazole derivatives as xanthine oxidase inhibitors. Different combinations of 15 training and 6 test compounds were 1, 3, 9, 13, 16, 19 Model 5 -compound no 1, 5, 9, 13, 15, 16 used for model generation. Alignment was based on atom-by-atom matching method. Many CoMFA models were obtained, of those only 5 models from systematic search conformation were selected based on higher q 2 and r 2 pred values.
CoMFA Model Analysis
Ligand-based CoMFA models was generated using different combinations of training set and test compounds. Based on higher q 2 and r 2 pred values only 5 models from systematic search were selected. The statistical values of the 5 models from different alignments are tabulated in Table 2 for systematic search. The best statistics were found in Model 1 having a cross-validated q 2 of 0.698 with five components and non-cross-validated correlation coefficient (r 2 ) of 0.992 with Fisher value as 236.431, and an estimated standard error of 0.068. The predictive ability of the best CoMFA models was found to be r 2 pred 0.653. Predicted and experimental pIC 50 and their residual values in Table 3 and their corresponding scatter plot is depicted in Fig. 2 .
Mapping of CoMFA Contour Maps
The CoMFA contour map for the generated models was analysed to explore the important structural features. The steric and electrostatic contour map obtained for systematic search alignment based CoMFA model are displayed in Fig. 3 and 4 . The steric interactions are represented by green and yellow contours. The green steric contour near the R 3 position indicates that bulkier substituents are preferred at this position. Thus, compounds 20, 21 and 6 with bulkier substituents at these positions are more active than compounds which have smaller substituents at the R 3 position. The electrostatic interactions are represented by red and blue contours. The blue contours represent that the electropositive substituents are favored in that region. The electrostatic contour plot shows that there is a big blue colored region near the R 3 position. Electro positive group linked to this position will enhance the biological activity. For example, compounds 16, 17 and 18, which are substituted with 1-(methylsulfonyl)propane, N-propylacetamide and N-propylmethanesulfonamide at that position is in direct contact with the big blue contour map. The red contours represent that the electronegative substituents are favored in that region. For example, the substituents at the R 3 position of compounds 1 and 20 are in direct contact with the red contour map, which reduce the biological activity.
Conclusion
In this study, we have developed CoMFA models of 2-(indol-5-yl) thiazole derivatives as xanthine oxidase inhibitors. CoMFA models with good cross-validated q 2 values and predictive ability were obtained. The statistical results showed the important structural alignments required for the inhibitory activity of the 2-(indol-5-yl) thiazole derivatives. The results correlate the structural features with the inhibitory activities against xanthine oxidase and provide valuable information about characteristics of inhibitors. The present CoMFA study revealed that the R 3 position of the structure is important in influencing the biological activity of the inhibitors. Electro positive groups and bulkier substituents linked to this position enhance the biological activity. The results obtained from this study have thrown light on the important structural and chemical features in designing and developing new potent novel inhibitors for xanthine oxidase.
